Tandem CD20-CD19-directed non-cryopreserved CAR T cells - zamtocabtagene autoleucel (Zamto-Cel) in patients with relapsed/refractory diffuse large B cell lymphoma - interim results from a phase 2 pivotal study (DALY II USA)

According to phase 2 data presented during the 2025 Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR, among patients with relapsed/refractory DLBCL in the modified intention-to-treat population, the CD19/CD20-targeted CAR T-cell therapy zamtocabtagene autoleucel demonstrated an overall response rate of 72.8%, including a complete remission rate of 50.8%.